Gosset Inventiva General Information
Inventiva’s lead candidate lanifibranor is in a pivotal Phase III trial (“NATiV3”) for NASH/MASH. Positive results were reported from the LEGEND Phase IIa study combining lanifibranor with empagliflozin in patients with NASH/MASH and type 2 diabetes in March 2024. The odiparcil program for MPS VI is suspended pending strategic review. Two additional preclinical programs are ongoing, including an oncology candidate targeting the Hippo pathway
Contact Information
France
Drug Pipeline
Key Partnerships
AbbVie – collaboration on ABBV‑157 for moderate to severe psoriasis; milestone payments and royalties possible if successful., Hepalys Pharma – exclusive licensing agreement to develop/commercialize lanifibranor in Japan/South Korea., Sino Biopharm – partnership/licensing agreement., CTTQ – milestone payments related to development of lanifibranor in China.
Inventiva Funding
| Deal Type | Date | Amount | Status | Stage |
|---|---|---|---|---|
| Investment | Oct 15, 2025 | $100.0M | Completed | Phase 3 |